Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study

Jing Chen, Fangshu Guan, Zhipeng Cheng, Yingying Wu, Lin Liu, Lu Zhang, Fang Liu, Guohui Cui, Heng Mei, Fanjun Cheng, Yi Zhao, Jun Fang

Open source

DOI: 10.3389/fimmu.2026.1973646
Published: 2026-10-21
Container: Frontiers in Immunology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1973646,
  title = {Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study},
  author = {Jing Chen and Fangshu Guan and Zhipeng Cheng and Yingying Wu and Lin Liu and Lu Zhang and Fang Liu and Guohui Cui and Heng Mei and Fanjun Cheng and Yi Zhao and Jun Fang},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1973646},
  url = {https://doi.org/10.3389/fimmu.2026.1973646}
}

RIS

TY  - JOUR
TI  - Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study
AU  - Jing Chen
AU  - Fangshu Guan
AU  - Zhipeng Cheng
AU  - Yingying Wu
AU  - Lin Liu
AU  - Lu Zhang
AU  - Fang Liu
AU  - Guohui Cui
AU  - Heng Mei
AU  - Fanjun Cheng
AU  - Yi Zhao
AU  - Jun Fang
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1973646
UR  - https://doi.org/10.3389/fimmu.2026.1973646
ER  -

APA

Chen, J., Guan, F., Cheng, Z., Wu, Y., Liu, L., Zhang, L., Liu, F., Cui, G., Mei, H., Cheng, F., Zhao, Y., & Fang, J. (2026). Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1973646

Source records

crossref · retrieved 2026-11-07T00:32:34.812Z